Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials

Laurie E. Gaspar, Charles Scott, Marvin Rotman, +5

International Journal of Radiation Oncology*Biology*Physics

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer

W. T. Sause, Charles Scott, S. Taylor, +9

JNCI Journal of the National Cancer Institute

Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol

Chandra P. Belani, Hak Choy, P. Bonomi, +4

Journal of Clinical Oncology

A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the radiation therapy oncology group (RTOG) 9104

Kevin Murray, Charles Scott, Harvey M. Greenberg, +7

International Journal of Radiation Oncology*Biology*Physics

Unresected Brain MetastasesNeuro-oncologySurgical OncologyRadiation TherapyAccelerated Hyperfractionation +7

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.

Jack Lee, Charles Scott, Ritsuko Komaki, +5

Journal of Clinical Oncology

Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma—Possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: Report of the radiation therapy oncology group protocol 8302

Diana F. Nelson, Walter J. Curran, Charles Scott, +8

International Journal of Radiation Oncology*Biology*Physics

Radiation MedicineRadiation TherapyMedicineRadionuclide TherapyCancer Treatment +8

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies

Benjamin Movsas, Charles Scott, William T. Sause, +10

International Journal of Radiation Oncology*Biology*Physics

Adaptive RadiotherapyRadiation MedicineRadiation TherapyMedicineTreatment Intensification +6

A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404

Michael D. Prados, Charles Scott, Howard M. Sandler, +9

International Journal of Radiation Oncology*Biology*Physics

Rtog 9404Neuro-oncologyRadiation MedicineGliomaRadiation Therapy +9

Improved Survival, Quality of Life, and Quality-Adjusted Survival in Breast Cancer Patients Treated With Efaproxiral (Efaproxyn) Plus Whole-Brain Radiation Therapy for Brain Metastases

Charles Scott, John H. Suh, Baldassarre Stea, +2

American Journal of Clinical Oncology

Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or ≤ 20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients

C. Coughlin, Charles Scott, Corey J. Langer, +3

International Journal of Radiation Oncology*Biology*Physics

Adaptive RadiotherapyNeuro-oncologyTwo-arm Rtog TrialPhase IiRadiation Therapy +8